ClinicalTrials.gg
CompletedNCT06266091Updated Jun 17, 2026

Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody

A Phase 2 interventional study of M701 and paracentesis in Malignant Ascites, sponsored by Wuhan YZY Biopharma Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Wuhan YZY Biopharma Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Nov 2021, registered Jan 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 43 studies in Ascites with a site in China — 14 open to participants now, 16 under way, 1 of them phase 3. Ascites · China.

Enrollment
12th of 37
115 · median 48
Started
2021
with 5 others
Phase 2
11 of 43
4 open now
Registered
28th of 43
by date
Lead sponsor
2 of 43
Wuhan YZY Biopharma Co., Ltd.

Among the 43 studies in Ascites with a site in China, this one is the 12th largest by enrollment of the 37 interventional ones that give a count, is one of 6 that started in 2021, is one of 11 in phase 2, and was the 28th registered.

Ascites

248 studies on the registry are indexed under Ascites; 57 are open to participants now.

Browse Ascites studies →

Open to participants now

14 of the 43 studies in Ascites with a site in China are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 40 Ascites studies recruiting now, 21 (53%) set no upper age limit and 12 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Ascites with a site in China, or all of them as a file.
02

Study summary

A Phase II, Randomized, Open-label, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of M701 in treating Patients with Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer combined with Systemic Therapy.

Read the detailed description

The phase II study is a controlled, open-label trial designed to assess the effectiveness and safety of M701 intra-peritoneal infusion for controlling malignant ascites in patients with gastrointestinal and ovarian cancer who are also receiving systemic therapy.

A total of 80 patients with malignant ascites caused by gastrointestinal or ovarian cancer will be randomly assigned to two treatment arms in a 1:1 ratio. These patients must have experienced disease progression or intolerance after receiving at least two lines of systemic therapy. Both treatment arms will receive the systemic therapy, but the test arm will additionally receive M701 intra-peritoneal infusion, while the control arm will undergo paracentesis only.

The primary endpoint of the study will be the puncture-free survival, which evaluates the efficacy of M701 in controlling malignant ascites. Secondary endpoints include the objective response rate (ORR) of malignant ascites, progression-free survival (PFS), overall survival (OS), quality of life (QOL), and safety profiles. The number of EpCAM-positive cells in the malignant ascites will be measured using flow cytometry before and after treatment with M701.

03

Conditions studied

  • Malignant Ascites

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand and voluntarily sign the written form.
  • or pathologically confirmed epithelial , including advanced gastric cancer or colorectal cancer that has failed at least two , or platinum-resistant advanced ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma.
  • Clinical diagnosis of malignant ascites with a moderate or higher amount of ascites. Moderate or higher is defined as having a volume of ascites ≥1L based on CT assessment or actual drainage of ≥1L.
  • The time interval between the most recent anti-tumor treatment and the first dose of M701 must meet the following criteria:

Intraperitoneal treatment: ≥2 weeks since the most recent intraperitoneal treatment.

  • Adverse events (AEs) from previous treatments have recovered to grade ≤1 (excluding other AEs deemed by the investigator not to affect the safety of the study drug, such as hair loss).
  • (ECOG) performance status (PS) of 0-2. Estimated survival time ≥8 weeks.
  • Organ function levels must meet the following requirements:

Hematology: (ANC) ≥1.5 × 10\^9/L, ≥80 × 10\^9/L, ≥8.5 g/dL, lymphocyte ratio (lymphocyte count/leukocyte count) ≥10% (without transfusion within 14 days).

Liver function: Total ≤1.5 times the (ULN), (AST) and alanine aminotransferase (ALT) ≤3 times ULN (AST and ALT ≤5 times ULN allowed in the presence of liver ).

Serum albumin ≥28 g/L. Renal function: Serum creatinine ≤1.5 times ULN.

Exclusion criteria

Exclusion Criteria:

  • Patients who have previously received M701 or any antibody-based drugs targeting EpCAM and/or CD3 within the 4 months prior to the first dose.
  • Patients with microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) colorectal cancer who have not previously received immunotherapy.
  • Patients who have undergone major surgery within the 4 weeks prior to the first dose.
  • Patients with extensive liver (tumor volume occupying approximately >70% of total liver volume).
  • Active infections requiring intravenous antibiotics within 14 days before the first dose.
  • Severe diarrhea ( grade ≥2).
  • Severe respiratory distress requiring oxygen therapy.
  • Active diseases, except for the following conditions that are allowed for screening: type 1 diabetes, controlled hypothyroidism with replacement therapy only, skin diseases that do not require systemic treatment。
  • Other severe medical conditions that may limit the patient's participation in the trial。
  • Impaired cardiac function with (NYHA) class 3 or 4.
  • Occurrence of complete intestinal obstruction within 30 days before the first dose, or diagnosis of incomplete intestinal obstruction deemed unsuitable for participation in the trial based on symptoms and signs as determined by the investigator.
  • Inability to adequately drain ascites due to objective reasons (including loculated ascites).
  • Confirmed portal vein obstruction.
  • History of immunodeficiency, including positive test.
  • Active virus infection, active virus infection, active syphilis, or positive HIV antibody.
  • Pregnant or lactating women.
  • Patients with fertility requirements during or within 6 months after treatment.
  • Known history of neurological or psychiatric disorders deemed by the investigator to affect cognitive function or compliance, including unstable epilepsy, dementia, schizophrenia, etc.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
115 participants (actual)

Study arms

  • Experimental
    M701 group

    M701 will be administered via intra-peritoneal infusion following sufficient drainage of malignant ascites. The treatment regimen consists of a leading dose of 50μg on Day 1, followed by three infusions of the full dose of 400 μg M701 on Days 4, 11, and 18. If well tolerated, patients will continue to receive M701 infusions every 2 weeks as maintenance treatment. Additionally, these patients will receive systemic therapy as determined by the investigator.

    Drug: M701

  • Active comparator
    Control group

    Patients in the control group will undergo paracentesis on Day 1 and Day 18. If necessary, they may receive additional paracentesis during this period. Additionally, these patients will receive systemic therapy as determined by the investigator.

    Drug: paracentesis

Interventions

  • DrugM701

    Intra-peritoneal infusion of M701 combined with system therapy

  • Drugparacentesis

    paracentesis combined with system therapy

06

What researchers measure

Primary outcomes

  1. Puncture-free survival, PuFS

    The time to the next puncture/drainage or death

    Time frame: From the time of 4th dosing (Day 18) to the next puncture/drainage or death (up to 6 months)

Secondary outcomes

  1. objective response rate (ORR) of malignant ascites

    The change of precentage of malignant ascites volume from the baseline by the image evaluation

    Time frame: From the time of 4th dosing (Day 18) to the next puncture/drainage or death (up to 180 days)re/drainage or death (up to 6 months)

  2. Progression-free Survival, PFS

    The time to disease progression assessed by the imaging evaluation or toxicity or death

    Time frame: From the time of first dosing (Day 1) until disease progression or toxicity intolerance or death (up to 6 months).

  3. Overall survival, OS

    The time to death

    Time frame: From the time of first dosing (Day 1) until death (up to 6 months).

  4. Safety profiles

    frequency, relationship and seriousness of adverse events

    Time frame: From the time of first dosing (Day 1) until one month after the EOT (up to 6 months).

  5. Positive rate of ADA and Nab in serum

    The positive rate of Anti-Drug Antibody (ADA) and Neutralizing antibody (Nab) in the serum during the study

    Time frame: From the time of first dosing (Day 1) until the EOT (up to 6 months).

  6. The EpCAM expression in ascites

    Measure the count of EpCAM postive cells in the ascites before and after M701 treatment

    Time frame: From the time of first dosing (Day 1) until the EOT (up to 6 months).

  7. Trough serum concentration (Ctrough)

    The lowest concentration of M701 in the serum in one treatment cycle

    Time frame: 6 months (anticipated)

  8. Peak serum concentration (Cmax)

    The highest concentration of M701 in the serum in one treatment cycle

    Time frame: 6 months (anticipated)

07

Study locations

1 site
  • The First Medical Center of Chinese PLA General Hospital
    Beijing, Beijing Municipality 100141, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Feb 2024, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2024
First posted
Feb 20, 2024
StartActual
Nov 24, 2021
Primary completionActual
Feb 14, 2024
CompletionActual
Aug 1, 2024
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06266091
Lead sponsor
Wuhan YZY Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Nov 24, 2021
Primary completion
Feb 14, 2024
Completion
Aug 1, 2024
Last update
Jun 17, 2026

Study contacts

Jianming Xu, MD
principal investigator · The First Medical Center of Chinese PLA General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion